Clinical Trials on Relapsed/Refractory Solid Tumor Malignancies or Lymphoma in South Africa

Total 251 results

Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)

Relapsed or Refractory Solid Tumors

United States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Solid Tumor | Refractory Tumor | Relapsed Solid Neoplasm

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
Spago Nanomedical AB

Recruiting

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer (Tumorad)

Solid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid Tumor

Australia
CStone Pharmaceuticals
Bayer

Completed

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Advanced Refractory Solid Tumors

Australia
FBD Biologics Limited

Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Advanced Solid Tumor | Refractory Non-Hodgkin Lymphoma

Taiwan, United States
Sydney Children's Hospitals Network
German Cancer Research Center; Australian & New Zealand Children's Haematology... and other collaborators

Active, not recruiting

PRecISion Medicine for Children With Cancer (PRISM)

Childhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain Tumor

Australia
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

United States, Spain, Canada, Australia, Italy
Binacea Pharma, Inc.

Recruiting

Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors

Refractory Solid Tumors

Australia
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
MapKure, LLC

Recruiting

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Solid Tumor | B-Raf Mutation-Related Tumors

United States, Australia
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Antengene Biologics Limited

Recruiting

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE)

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

United States, Australia
Incyte Corporation

Terminated

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Metastatic Cancer | Solid Tumors | Advanced Malignancies

United States
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Jazz Pharmaceuticals

Completed

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (EMERGE-201)

Advanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies Agnostic

United States
The Hospital for Sick Children
Bristol-Myers Squibb

Terminated

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Refractory or Recurrent Hypermutated Malignancies | Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients

United States, France, Canada, Australia, Israel
Minghui Pharmaceutical Pty Ltd

Not yet recruiting

Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
DynamiCure Biotechnology

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Australia
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
Aadi Bioscience, Inc.

Active, not recruiting

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Malignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic Neoplasm

United States, Korea, Republic of, Puerto Rico
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Pfizer

Terminated

LGX818 for Patients With BRAFV600 Mutated Tumors (SIGNATURE)

Solid Tumor | Hematologic Malignancies

United States
Novartis Pharmaceuticals

Terminated

BGJ398 for Patients With Tumors With FGFR Genetic Alterations (CBGJ398XUS04)

Solid Tumor | Hematologic Malignancies

United States
Antengene Therapeutics Limited
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Australia, China
Seagen Inc.

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Acute Myeloid Leukemia | Solid Tumors | Acute Lymphoid Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Kite, A Gilead Company

Active, not recruiting

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24)

Relapsed or Refractory Large B-cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Malignant Glioma | Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Australian & New Zealand Children's Haematology...
The Hospital for Sick Children; Kazia Therapeutics Limited; Day One Biopharmaceuticals... and other collaborators

Not yet recruiting

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Childhood Cancer | Refractory Cancer | Recurrent Cancer | Childhood Solid Tumor | Childhood Brain Tumor

Australia, Canada
Amgen
Merck Sharp & Dohme LLC

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (HARBOUR)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

United States, Germany, Spain, Australia, Netherlands, France
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

B-cell Lymphoma | Hodgkin's Lymphoma | Relapsed or Refractory Lymphoproliferative Malignancies | Peripheral T-cell Lymphoma | Waldenstrom's Macroglobulinemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
Adlai Nortye Biopharma Co., Ltd.

Recruiting

First in Human, Dose Escalation Study of AN4005

Advanced Solid Tumor | Advanced Lymphoma

United States, China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo)

Relapsed or Refractory Follicular Lymphoma

United States, China, Korea, Republic of, Taiwan, Spain, United Kingdom, Australia, France, Germany, Japan, Turkey, Brazil, Poland, Ukraine, Italy, Russian Federation
AstraZeneca

Active, not recruiting

Durvalumab and Tremelimumab for Pediatric Malignancies

Pediatric Cancer | Hematological Malignancies | Solid Tumor Pediatric

Spain, Italy, United States, United Kingdom, France, Netherlands, Germany
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)

Advanced or Metastatic Solid Tumors

Chile, Hungary, Korea, Republic of, South Africa, Spain, Japan
Blueprint Medicines Corporation

Recruiting

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

CNS Tumor | Solid Tumor, Unspecified, Child | Relapsed Solid Neoplasm

United States, Korea, Republic of, United Kingdom, France, Canada, Australia, Austria, Germany, Italy
Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
CStone Pharmaceuticals

Recruiting

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Advanced Solid Tumor | Advanced Lymphoma

China, Australia, United States

Clinical Trials on Relapsed/Refractory Solid Tumor Malignancies or Lymphoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations